This is the text extract for Topical anti-acne treatment (adapalene) and urea funding approved., browse documents here.

25 August 2010

Topical anti-acne treatment (adapalene) and urea funding approved

PHARMAC is pleased to announce the approval of an agreement with Galderma Australia Pty Limited for adapalene 0.1% cream and gel (Differin). Differin is a topical retinoid used for the treatment of acne vulgaris. In addition, as a result of the agreement, the subsidy for urea 10% cream (Nutraplus) will be increased to match the current manufacturer’s price so that it becomes fully funded.

Summary of the decision

Adapalene (Differin) Differin will be listed, fully funded, in Section B of the Pharmaceutical Schedule with no Special Authority or endorsement restrictions, from 1 October 2010, at a subsidy and price of $22.89 per 30 g OP (ex-manufacturer, excluding GST). Each subsidised dispensing of Differin will be limited to a maximum of 30 g (i.e. 1 pack). A confidential rebate will apply to all sales of Differin, which will reduce the net subsidy paid by PHARMAC. Urea (Nutraplus) Nutraplus will be fully funded in Section B of the Pharmaceutical Schedule from 1 October 2010, at a subsidy and price of $3.07 per 100 g (ex-manufacturer, excluding GST). If you have any queries about this funding decision you can call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.

What feedback was received?

We appreciate all of the feedback that we received and acknowledge the time people took to respond to consultation. All consultation responses were considered in their entirety before making a decision on the proposal. All responses were supportive of the proposal to fully subsidise adapalene and urea.

More information If you have any questions about this decision, you can call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.

A373005 - T10-458

1 of 1